A Goal For AIDS
i-Newswire,
2011-11-22
Bid on FIFA 2010 World Cup soccer ball plus lunch at Planet Hollywood International.
Semprus BioSciences Awarded $1 Million U.S. Army Grant to Develop "Anti-Biofilm Trauma Devices"
i-Newswire,
2011-10-19
Semprus BioSciences today announced it has received a $1 million grant from the U.S. Army Telemedicine & Advanced Technology Research Center (TATRC) to develop the world's first orthopedic devices designed to reduce biofilm formation.
Handwash Reminders In Hospitals In Time For Global Handwashing Day
i-Newswire,
2011-10-11
An infection prevention device called the Handwash Reminder is donated to hospitals across the nation to help enforce hand washing and prevent Healthcare Acquired Infections (HAI's)
GeoVax Labs’ CSO and Chairman Receive Academic Honors
i-Newswire,
2011-09-29
CSO Harriet L. Robinson Honored as Distinguished Emeritus Faculty;
Chairman David A. Dodd To Receive Alumni Award from Georgia State University
Nail-fungus.info Provides The Best Solutions For The Toenail Fungus Treatment
i-Newswire,
2011-09-28
http://www.nail-fungus.info/ offers the best solutions one can adopt and apply in order to get rid of the toenail fungal infection .
World AIDS Day Rowboat Named At Brazilian Day In New York City On Sunday
i-Newswire,
2011-09-01
During a pre-boat christening ceremony, AIDS activist Victor Mooney of Forest Hills reveals the name of his new boat before a test row from Rio de Janeiro to Sao Paulo later this month.
Geovax Awarded $3.6 Million Grant By U.S. Government For Its HIV/AIDS Vaccine Program
i-Newswire,
2011-08-16
U.S Government Continues Support for Clinical Development of Adjuvanted Vaccine
IVD and Medical Device Industry Veteran Randy Vader Launches IVD Consultants
i-Newswire,
2011-06-28
Randy Vader today announced the launch of IVD Consultants, a new consulting and contract firm. IVD Consultants will provide a wide range of Regulatory, Clinical and Quality consulting and contract services to the IVD and Medical Device industries.
One Company Takes Next Step to Getting In-Home HIV Test to Market
i-Newswire,
2011-06-27
According to the CDC, about 20 percent of Americans with HIV don’t know it, greatly increasing their risk of transmitting the virus.
GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
i-Newswire,
2011-06-23
Los Angeles-Based AIDS Research Alliance Selected as Site to Test Therapeutic vaccine
GeoVax Trial Results Establish a New Benchmark for Preventative HIV Vaccine Model
i-Newswire,
2011-06-08
Non Human Primate Study Demonstrates Unprecedented 70% Prevention of Infection
Pharmacy OneSource Announces Webinar on Infection Prevention Reporting
i-Newswire,
2011-05-19
Reviewing Requirements for Surgical Site Infections and Using Standardized Infection Ratios
NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase(R) Study of 26 Patients With Chronic Non-Healing Wounds
i-Newswire,
2011-04-19
Highlights the Efficacy of NovaBay's Novel Anti-Infective. Highlights the Efficacy of NovaBay's Novel Anti-Infective
Encouraged by Early Clinical Studies, A Biotech Company Expands Its HIV/AIDS Vaccine Program
i-Newswire,
2011-04-14
GeoVax has decided to expand its preventative HIV/AIDS vaccine development effort in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH) and the HIV Vaccine Trials
To Prevent the Donation of Infected Organs, Attention Turns to More Rapid Testing
i-Newswire,
2011-03-28
A new generation of rapid point-of-care tests for HIV and HEP B/C—such as those being developed by Chembio—could help ensure that donated organs are healthy, and that unfortunate incidents like the one reported in New York City do not reoccur.
Norovirus Outbreak: Hit 2 Hospitals
i-Newswire,
2011-03-23
The Norovirus has spread out in 2 community hospitals leaving patients unattended by their loves ones. Visitors are not allowed to visit until hospital being cleared from the virus. Experts advised was to use natural cleaning products.
Dr Siddharth Jondhale Nominated for the Albert Schweitzer, Maharashtra & Western India Delighted
i-Newswire,
2011-03-07
Dr. Siddharth M. Jondhale, the young Doctor hailing from Nanded, Maharashtra (located in the Western part of India) working judiciously for the cure of the disease HIV, has been selected for the Albert Schweitzer Award.
GeoVax Announces Publication of Phase 1 Clinical Trial in The Journal of Infectious Diseases
i-Newswire,
2011-02-23
The article, titled “Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles,” will appear in the March 1 issue of The Journal of Infectious Diseases.
GeoVax Launches Second Clinical Site To Test The Therapeutic Benefit of HIV Vaccine
i-Newswire,
2011-02-09
University of Alabama at Birmingham to Serve as Second Site for Ongoing Clinical Trial
PolyMedix Promotes Bozena Korczak to Senior Vice President, Drug Development and Chief Development Officer
i-Newswire,
2011-01-25
PolyMedix announces the promotion of Bozena Korczak, Ph.D. to Senior Vice President, Drug Development and Chief Development Officer.
Handwash Reminder Sells Over 250 Pcs In One Week
i-Newswire,
2010-12-19
Pratts Creative Ideas, LLC the inventors of the Handwash Reminder sells a whooping 250 pcs in just one week. This is a good sign that people are taking handwashing seriously.
NGOs Unite to Call HIV Pharmaceutical Manufacturers to the Medicines Patent Pool
i-Newswire,
2010-12-15
NGOs unite and send letters to pharmaceutical manufacturers urging their participation in the UNITAID patent pool
GeoVax Awarded Federal Grant Under The Qualifying Therapeutic Discovery Project Program
i-Newswire,
2010-11-04
The grant was awarded following GeoVax’s submission for consideration of its HIV/AIDS vaccine research and development project to the U.S. Secretary of Health and Human Services.
Novel Non-antibiotic Anti-infective Successfully Treats Impetigo Patients Including 100% Infected with MRSA
i-Newswire,
2010-10-25
NovaBay Pharmaceuticals, Inc., is innovating a new class of drugs, known as Aganocide® compounds, that mimic the body’s natural defense against infection. The Aganocides could potentially equal or exceed the utility of antibiotics.
NovaBay Pharmaceuticals Reports Status of Phase 2 Proof of Concept Clinical Trial for Viral Conjunctivitis
i-Newswire,
2010-10-18
Alcon and NovaBay will be analyzing the microbiological and clinical efficacy of the drug vs. placebo in all 81 adenovirus positive patients enrolled in the trial and plan to report on these analyses in early 2011.